Analyst Expectations for Arrowhead Pharma's Future
Portfolio Pulse from Benzinga Insights
Analysts have provided various ratings for Arrowhead Pharma (NASDAQ:ARWR) within the last quarter, with a total of 4 bullish, 2 somewhat bullish, and 1 indifferent. The average 12-month price target for Arrowhead Pharma, according to 7 analysts, is $62.14, a decrease of 21.34% from the previous average price target of $79.00.
September 19, 2023 | 3:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Analysts' ratings for Arrowhead Pharma are mostly bullish, but the average 12-month price target has decreased significantly.
The majority of analysts are bullish on Arrowhead Pharma, indicating a positive outlook. However, the significant decrease in the average 12-month price target could suggest a potential downside, leading to a neutral short-term impact.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100